NPRWill State Voters Continue To Pour Money Into Stem Cell Research?NPRThe year was 2004, and according to certain TV ads in California, great medical breakthroughs might be just around the corner. In these political ads, celebrities Michael J. Fox and… Continue reading
Synthetic Biology Global Market 2017: Key Players: ACTIVE MOTIF, AGRIVIDA ALGENUITY, AMBRX INC., ARZEDA …MENAFN.COMThe study scope includes core products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, product… Continue reading
Synthetic Biology Global Market 2017: Key Players: ACTIVE MOTIF, AGRIVIDA ALGENUITY, AMBRX INC., ARZEDA …Digital JournalThe study scope includes core synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, s… Continue reading
[Immunotherapy in renal cell carcinoma: A booming clinical research].UroTodayNivolumab, an anti-PD1 immune control point inhibitor, is the first treatment that has improved the overall survival of patients after first-line metastatic renal cell carcino… Continue reading
Synthetic virus to tackle antimicrobial resistanceBSA bureau (press release)Antibiotic resistance has become an ever-growing global challenge, with more than 700,000 people across the world dying from drug resistant infections every year. As a result, … Continue reading
Business Wire (press release)Synpromics Announces New Partnership with UCL to Develop Novel Gene Therapies for Blood-Based DisordersBusiness Wire (press release)EDINBURGH, Scotland–(BUSINESS WIRE)–Synpromics Ltd, the leader in gene control, announces… Continue reading
Business Wire (press release)Synpromics Announces New Partnership with UCL to Develop Novel Gene Therapies for Blood-Based DisordersBusiness Wire (press release)EDINBURGH, Scotland–(BUSINESS WIRE)–Synpromics Ltd, the leader in gene control, announces… Continue reading
Novartis, Spark in vision-loss gene therapy dealMarketWatchNovartis AG (NOVN.EB) has reached a licensing agreement with Spark Therapeutics Inc. ONCE, -2.10% to commercialize outside the U.S. a gene therapy for a form of vision loss, the companies said … Continue reading